FAST:Towards safe and effective subcutaneous immunotherapy of persistent life-threatening food allergies

Autor: Adriano Mari, Alberto Martínez, Claudio Nicoletti, Laurian Zuidmeer-Jongejan, Enrico Scala, Anna Lewandowska-Polak, Hans Huber, Rudolf Valenta, Serge A. Versteeg, Birgit Linhart, Heidi J. Schnoor, Paula Garosi, George A. Stavroulakis, Marek L. Kowalski, Nikos Papadopoulos, Ronald van Ree, Juan A. Asturias, Bettina M. Jensen, Angela Neubauer, Bernard Maillere, Clare Mills, Lars K. Poulsen, Ines Swoboda, Frank Stolz, Rob Van Den Hout, Montserrat Fernandez-Rivas, Marianne Witten, Joyce I. Boye, Stef J. Koppelman, Neil M. Rigby, Rosa Ferrara, Michael Clausen, Carsten Bindslev-Jensen, Antonio Portolés, Lars Blom, Dirk Jan Opstelten, Sigurveig T. Sigurdardottir
Přispěvatelé: Amsterdam institute for Infection and Immunity, Experimental Immunology, Amsterdam Public Health
Jazyk: angličtina
Rok vydání: 2012
Předmět:
Zdroj: Zuidmeer-Jongejan, L, Fernandez-Rivas, M, Poulsen, L K, Neubauer, A, Asturias, J, Blom, L, Boye, J, Bindslev-Jensen, C, Clausen, M, Ferrara, R, Garosi, P, Huber, H, Jensen, B M, Koppelman, S, Kowalski, M L, Lewandowska-Polak, A, Linhart, B, Maillere, B, Mari, A, Martinez, A, Mills, C E, Nicoletti, C, Opstelten, D-J, Papadopoulos, N G, Portoles, A, Rigby, N, Scala, E, Schnoor, H J, Sigursdottir, S, Stavroulakis, G, Stolz, F, Swoboda, I, Valenta, R, van den Hout, R, Versteeg, S A, Witten, M & van Ree, R 2012, ' FAST : Towards safe and effective subcutaneous immunotherapy of persistent life-threatening food allergies ', Clinical and Translational Allergy, vol. 2, no. 1, pp. 5 . https://doi.org/10.1186/2045-7022-2-5
Clinical and Translational Allergy; Vol 2
Clinical and translational allergy, 2(1). BioMed Central
Clinical and Translational Allergy
Clinical and Translational Allergy, Vol 2, Iss 1, p 5 (2012)
ISSN: 2045-7022
DOI: 10.1186/2045-7022-2-5
Popis: The FAST project (Food Allergy Specific Immunotherapy) aims at the development of safe and effective treatment of food allergies, targeting prevalent, persistent and severe allergy to fish and peach. Classical allergen-specific immunotherapy (SIT), using subcutaneous injections with aqueous food extracts may be effective but has proven to be accompanied by too many anaphylactic side-effects. FAST aims to develop a safe alternative by replacing food extracts with hypoallergenic recombinant major allergens as the active ingredients of SIT. Both severe fish and peach allergy are caused by a single major allergen, parvalbumin (Cyp c 1) and lipid transfer protein (Pru p 3), respectively. Two approaches are being evaluated for achieving hypoallergenicity, i.e. site-directed mutagenesis and chemical modification. The most promising hypoallergens will be produced under GMP conditions. After pre-clinical testing (toxicology testing and efficacy in mouse models), SCIT with alum-absorbed hypoallergens will be evaluated in phase I/IIa and IIb randomized double-blind placebo-controlled (DBPC) clinical trials, with the DBPC food challenge as primary read-out. To understand the underlying immune mechanisms in depth serological and cellular immune analyses will be performed, allowing identification of novel biomarkers for monitoring treatment efficacy. FAST aims at improving the quality of life of food allergic patients by providing a safe and effective treatment that will significantly lower their threshold for fish or peach intake, thereby decreasing their anxiety and dependence on rescue medication.
Databáze: OpenAIRE
Externí odkaz: